<<
>>

Список литературы

1. Абдурахмонов А. Синдром раздраженного кишечника (некоторые аспекты патогенеза, диагностики и лечения): дис. канд. мед. наук. – Душанбе., 2005.

2. Акарачкова Е.С., Шварков С.Б.

Тревога в неврологической и общесоматической практике. Современные аспекты терапии // РМЖ. – 2007. – Т. 15. – № 5. – С. 3-6.

3. Алексеенко С.А., Крапивная О.В. Диагностика и лечение синдрома раздраженного кишечника // Тихоокеанский медицинский журнал. – 2005. – № 1. – С. 53–55

4. Ардатская М. Д., Минушкин О. Н. Современные принципы диагностики и фармакологической коррекции // Гастроэнтерология, приложение к журналу Consilium Medicum. – 2006. – Т. 8. – №2. – C.

5. Ардатская М.Ф. Клиническое значение короткоцепочечных жирных кислот при патологии желудочно-кишечного тракта: дис. докт. мед. наук. – М., 2003.

6. Баринов Э.Ф., О.Н. Сулаева РЖГГК. – 2012. – Т.21. – №2. – С.4-13.

Роль серотонина в физиологии и патологии желудочно-кишечного тракта

7. Бельмер С.В., Гасилина Т.В. Кишечная микрофлора и антибактериальная терапия // Consilium Medicum. Педиатрия. – 2005. –

№ 1. – С. 14–16.

8. Бельмер С.В., Малкоч А.В. Кишечная микрофлора и значение пребиотиков для ее функционирования // Лечащий врач. – 2006. – №4.

– C. 60-65.

9. Бондаренко В. М. Молекулярно-клеточные механизмы терапевтического действия пробиотических препаратов // Фарматека. 2010. – Т. 196. – С. 26-32.

10. Воробьев А.А. Микробиология и иммунология. М.: Медицина. 1999г.

11. Воробьева О.В. Стресс и депрессия // Психиатрия и психофармакотерапия. – 2007. – N 4. – С.21-24.

12. Всемирная Гастроэнтерологическая ассоциация. Практические рекомендации. Пробиотики и пребиотики. Май 2008г.

13. Гандур Х.М., Удовиченко Т.Г. и соавт. Аноректальная манометрия в дифференциальной диагностике функциональных расстройств ануса и прямой кишки. Материалы 2-ой науч.-практич. конфер. – Хабаровск.

– 2000. – С. 105–18.

14. Звягинцева Т.Д., Гриднева С.В. Синдром раздраженного кишечника, дисбиоз, Энтерожермина // Новости медицины и фармации. – 2009. – Т. 17. – № 291.

15. Ивашкин В.Т. Основные понятия и положения фундаментальной иммунологии // РЖГГК. – 2008. – Т.18. – №4. – С. 4-13.

16. Ивашкин В.Т. Полуэктова Е.А. Функциональные расстройства желудочно-кишечного тракта. М.: МЕДпресс-информ. 2013г.

17. Ивашкин В.Т., Денисов Н.Л. Местный иммунитет и микробиоценоз при заболеваниях кишечника // РЖГГК. – 2009. – Т.19. – №6. – С.11-16.

18. Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М.: ГЭОТАР-Медиа. 2011г.

19. Ивашкин В.Т., Шептулин А.А., Склянская О.А. Синдром диареи. М., 2002.

20. Каширская Н. Ю. Значение пробиотиков и пребиотиков в регуляции кишечной микрофлоры // Русский медицинский журнал. – 2000. – №13.

– C. 14.

21. Козлов И.Г. Лекарственные воздействия через рецепторы врожденного иммунитета. 2005:zao-peptek@mtu-net.ru.

22. Колесников Д.Б. Синдром раздраженной толстой кишки (психосоматические соотношение типология, терапия): автореф. дис. канд. мед. наук. – М., 2000.

23. Корниенко Е.А. Современные принципы выбора пробиотиков // Детские инфекции. – 2007. – № 3. – C. 64-69.

24. Курбатова А.А. Патогенетическое и клиническое значение системы цитокинов и клаудинов у больных с синдромом раздражѐнного кишечника: дис. канд. мед. наук. – М., 2013.

25. Кучумова С.Ю., Полуэктова Е.А., Шептулин А.А., Ивашкин В.Т. Физиологическое значение кишечной микрофлоры // РЖГГК. – 2011. – Т.21. – №5.

26. Кучумова С.Ю., Шептулин А.А. Новое в изучении проблемы синдрома раздраженного кишечника // РЖГГК. – 2009. – Т. 19. – №4.

27. Маев И.В., Самсонов А.А. Терапевтическая тактика при синдроме избыточного бактериального роста в тонкой кишке // Сonsilium- medicum. – 2007. – Т. 9. – № 7. – С. 35-38.

28. Малкоч А.В., Бельмер С.В., Ардатская М.Д., Минушкин О.Н., Смирнова К.А. Показатели короткоцепочечных жирных кислот у детей с кишечным дисбиозом на фоне терапии лактулозой // Вопросы детской диетологии.

– 2007. – Т.5. – №1. – 72-73.

29. Олескин А. В., Ботвинко И. В., Кировская Т. А. Микробная эндокринология и биополитика // Вестник Московского университета. Серия «Биология». – 1998. – № 4. – С. 3–10.

30. Отраслевой стандарт 91500.11.0004-2003 Протокол ведения больных.

Дисбактериоз кишечника. – М. 2003.

31. Патрушев Л. И. Экспрессия генов. – М.: Наука, 2000.

32. Покровский В.И. Медицинская микробиология. М.: ГЭОТАР-Медиа.

2007г.

33. Полуэктова Е.А. Некоторые особенности патогенеза, клиники, диагностики и лечения больных с синдромом раздраженного кишечника: дис. канд. мед. наук. – М., 2002.

34. Радченко В.Г. Добрица В.П., Селиверстов П.В., Тетерина Л.А., Чихачева Е.А. Актуальные вопросы коррекции микробиоценоза кишечника. Учебно-методическое пособие. – СПб, 2012.

35. Рассохина О.А., Влияние серотонина на психологический статус у больных с синдромом раздраженной кишки // Гастроэнтерология. – 2010. – Клинические исследования.

36. Рупчев Г.Е. Психологическая структура внутреннего телесного опыта при соматизации (на модели соматоформных расстройств): Дис. канд. психол. наук. М., 2001.

37. Рязанский С.С., Гвоздев В.А. Короткие РНК и канцерогенез // Биохимия. – 2008. – Т.5 . – №73. – С. 640-655.

38. Саблин О.А. Возможности энтерокинетической терапии нарушений моторики кишечника при запоре // Фарматека. – 2013. – Т. 255. – № 2. – С. 1-6.

39. Спиваковский Ю.М., Шульгина Е.Н., Эйберман А.С., Герасименко Ю.К., Скупова О.В. Синдром раздраженного кишечника у детей в свете

«Римских критериев III» и роль иммуномодулирующей терапии в коррекции основных проявлений болезни // РМЖ. – 2010. – Т. 18. - №. 4 – С. 20.

40. Ткач С.М., Пучков К.С., Кузенко Ю.Г. Биологические эффекты оксидов азота в желудочно-кишечном тракте. Сучасная гастроентерология. – Т. 72. – № 4. – 2013.

41. Тхостов А.Ш., Ефремова О.В. Метод исследования интрацептивной семантики при ипохондрических синдромах // Тезисы докладов

Всесоюзной конференции «Актуальные проблемы пограничной психиатрии».

М.; Витебск, 1989. Ч. 1. С. 110-112.

42. Шульпекова Ю.О. Кисломолочные бактерии: роль в регуляции кишечной перистальтики. РЖГГК. – 2010. – Т.20. – №3. – С. 68-73.

43. Яковлев А.А. Состояние системы: оксид азота – эндотелиновые пептиды – эндотелиальный фактор роста у больных с разными формами синдрома раздраженного кишечника // РЖГГК. – 2002. –

№ 5. – С. 66.

44. Afshari K., Ohman L., Isaksson S. et al. Assoсiation between proinflammatory serum cytokines and pathophysiological factors and symptoms in IBS // Gut. – 2010. – Vol. 59. – P. 136.

45. Alberts B., Johnson A., Lewis J. et al. Molecular Biology of the Cell // Garland Science. – 2008. – Vol. 5. – P. 1392.

46. Arumugam M. et al. Enterotypes of the human gut microbiome // Nature. – 2011. – Vol. 473 (7346). – P. 174-80.

47. Balsari A., Ceccarelli A., Dubini F., et al. The fecal microbial population in the irritable bowel syndrome // Microbiologica. – 1982. – P. 5. – P. 185–94.

48. Barrett E., Ross R.P., O'Toole P.W., Fitzgerald G.F., Stanton C. γ- Aminobutyric acid production by culturable bacteria from the human intestine // J. Appl. Microbiol. – 2012. – Vol. 113(2). – P. 411-7.

49. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function // Cell. – 2004. – Vol. 23. – № 116). – P. 281-97.

50. Beck А.Т., Ward C.H., Mendelson M., Mock J., Erbaugh J. An Inventory for Measuring Depression // Archives of General Psychiatry. – 1961. – Vol. 4. – Р. 561-71.

51. Belmonte L., Beutheu Youmba S., Bertiaux-Vandaële N. et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune

activation according to the disease subtype // PLoS One. – 2012. – Vol. 7. – P. 427-77.

52. Bercik P, Denou E, Collins J et al. The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice // Gastroenterology. – 2011. – Vol. 141. – P. 599-609

53. Bertiaux-Vandaële N., Youmba S.B., Belmonte L. et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype // Am. J. Gastroenterol. – 2011. – Vol. 106. – P. 2165-73.

54. Bhathena J., Martoni C., Kulamarva A., Urbanska A.M., Malhotra M., Prakash S. Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters // J. Med. Food. – 2009. – Vol. 12. – P. 310–9.

55. Biancone L. et al. Cytoskeletal proteins and resident flora // Dig. Liver Dis.

– 2002. – V. 34. – P. 34-36.

56. Blanco P., Palucka A.K., Pascual V. et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases // Cytokine Growth Factor Rev. – 2008. – Vol. 19. – № 1. – P. 41-52.

57. Blaut M., Collins M.D., Welling G.W., Dore J. et al. Molecular biological methods for studying the gut microbiota: The EU human gut flora project // Br. J. Nutr. – 2002. – Vol. 87 (Suppl 2). – P. 203-11.

58. Boroni Moreira AP, Fiche Salles Teixeira T., et al. Gut microbiota and the development of obesity // Nutr. Hosp. – 2012. – Vol. 27. – №.5. – P. 1408- 14.

59. Bravo J.A. et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve // Proc. Natl. Acad. Sci. USA. – 2011. – Vol. 108 (38). – Р. 6050-5.

60. Briejer MR, Akkermans LM Meulemans AL. 5-HT-induced neurogenic relaxations of the guinea-pig proximal colon: investigation into the role of ATP and VIP in addition to nitric oxide // Naunyn. Schmiedebergs. Arch. Pharmacol. – 1995. – Vol. 351. – P, 126-35.

61. Bures J., Cyrany J., Kohoutova D. et al. Small intestinal bacterial overgrowth syndrome // World J. Gastroenterol. – 2010. – Vol.16 (Suppl.24). – P. 2978–90.

62. Camilleri M. Serotonin in the gastrointestinal tract // Curr. Opin. Endocrinol.

Diabetes. Obes. – 2009. – Vol. 16(1). – P. 53-9.

63. Carroll I.M., Chang Y.H., Park J. et al. Luminal and mucosal-associated intestinal microbiota in patients with diarrhoea-predominant irritable bowel syndrome // Gut Pathog. – 2010. – Vol. 2. – P. 19.

64. Cash B.D., Chey W.D. Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation // Aliment. Pharmacol. Ther. – 2005. – Vol. 22. – № 11. – Р. 1047-60.

65. Chen C.L., Liu T.T., Yi C.H., Orr W.C. Evidence for altered anorectal function in irritable bowel syndrome patients with sleep disturbance // Digestion. – 2011. – Vol. 84. – P. 247-51.

66. Cherbut C. Effects of short-chain fatty acids on gastrointestinal motility // Physiological and clinical aspects of short-chain fatty acids / Eds. J.H. Cummings, J.L. Rombeau, T. Sakata. – UK: Cambridge, Cambridge Univ. Press, 1995. – P. 191.

67. Cherbut C. et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat // Am. J. Physiol. Gastrointest. Liver Physiol. –1998. – Vol.275. – Issue 6. – G1415-G1422.

68. Chokshi N.K., Guner Y.S., Hunter C.J. et al. The role of nitric oxide in intestinal epithelial injury and restitution in neonatal necrotizing enterocolitis // Semin. Perinatol. – 2008. – Vol. 32. – P. 92-99.

69. Choung R.S., Ruff K.C., Malhotra A. et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture // Aliment. Pharmacol. Ther. – 2011. – Vol. 33. – P. 1059-67.

70. Claesson M.J., Cusack S., O'Sullivan O. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly // Proc. Natl. Acad. Sci. USA. – 2011. – Vol. – 108. – Suppl. 1. – P. 4586-91.

71. Clarke G., Cryan J.F., Dinan T.G., Quigley E.M. Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria // Aliment. Pharmacol. Ther. – 2012. – Vol. 35. – P. 403-13.

72. Clarke G., McKernan D.P. et al. A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome // Front Pharmacol. – 2012. – Vol. 3. – P. 90.

73. Codling C., O'Mahony L., Shanahan F. et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome // Dig. Dis. Sci. – 2010. – Vol. 55. – P. 392–7.

74. Comelli E.M., Simmering R., Faure M. et al. Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota // Genomics. – 2008. – Vol. 91. – P. 70-7.

75. Corfield A.P., Myerscough N., Longman R. et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease // Gut. – 2000. – Vol. 47. – P. 589–94.

76. Creed F. Relationship between IBS and psychiatric disorders. // In Camilleri M., Spiller R.C. Irritable bowel syndrome. Diagnosis and treatment. W.B. Saunders, 2002. – P. 45-54.

77. Cummings J.H., Macfarlane G.T., Englyst H.N. Prebiotic digestion and fermentation // American Journal of Clinical Nutrition. – 2001. – Vol. 73. – Р. 415–20.

78. Dalmasso G., Nguyen H.T., Yan Y. et al. Microbiota modulate host gene expression via microRNAs // PLoS One. – 2011. – Vol. 29. – №.6 – P.4.

79. De Filippo C., Cavalieri D., Di Paola M. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa // Proc. Natl. Acad. Sci. USA. – 2010. – Vol. 17. – №107. – P. 14691-6.

80. De P.G., Nadal I., Medina M. et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children

// BMC Microbiol. – 2010. – Vol. 10. – P. 63.

81. Dennemont J., Roupas A., Heitz M. Differentiation of Campylobacter jejuni, C.coli, C.lary and C.fetus fatty acid profiles obtained by gas chromatography-mass spectrometry and by their hippurate hydrolysis // Mitt. Geb. Lebensmittelunters. Hyg. – 1992. – Vol. 83. – N 2. – P. 142-50.

82. Dinan T.G., Stanton C., Cryan J.F. Psychobiotics: a novel class of psychotropic // Biol. Psychiatry. – 2013. – Vol.15. – №74. – P. 720-6.

83. Dinan TG, Cryan JF. Melancholic microbes: a link between gut microbiota and depression? Neurogastroenterol Motil. – 2013. – Vol. 25. – №9. – P. 713-9.

84. Dlugosz A., Lindberg G. The expression of toll-like receptor 4 in colon mucosa is as up-regulated in irritable bowel syndrome as it is in inflammatory bowel disease // Gut. – 2010. – Vol. 59. – A 31.

85. Drossman D.A. Rome III: the new criteria // Chin. J. Dig. Dis. – 2006. – Vol. 7. – № 4. – P. 181-5.

86. Du T., Zamore P.D. MicroPrimer: the biogenesis and function of microRNA

// Development. – 2005. – Vol. 132 (21). – P. 4645-52.

87. Dunlop S.P., Hebden J., Campbell E. et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes //Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1288–94.

88. Floch M.H., Walker W.A., Madsen K., Sanders M.E., Macfarlane G.T., Flint H.J., Dieleman L.A., Ringel Y., Guandalini S., Kelly C.P., Brandt L.J. Recommendations for probiotic use-2011 update // J. Clin. Gastroenterol. – 2011. – Vol. 45. – Р. 168-71.

89. Ford A.C., Spiegel B.M., Talley N.J., Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta- analysis. – Clin. Gastroenterol. Hepatol. – 2009. – Vol.7. – P. 1279-86.

90. Forsythe P., Bienenstock J. Immunomodulation by commensal and probiotic bacteria // Immunol. Invest – 2010. – Vol. 39. – P. 429–48.

91. Foster J.A. Gut feelings: bacteria and the brain // Cerebrum. – 2013. – Vol.

1. – P. 9.

92. Frank D.N., St Amand A.L., Feldman R.A. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases // Proc. Natl. Acad. Sci. USA. – 2007. – Vol. 104. – P. 13780–5.

93. Fukumoto S. et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2003. – Vol. 284. – Issue 5. – R1269-R1276.

94. Gasbarrini A., Lauritano E.C., Gabrielli M. et al. Small intestinal bacterial overgrowth: diagnosis and treatment // Dig. Dis. – 2007. – N 25. – P. 237- 40.

95. Gershon M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome // J. Clin. Gastroenterol. – 2005. – Vol. 39. – Р. 184–193.

96. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea // J. Neurogastroenterol. Motil.

– 2010. – Vol. 16. – P. 40–46.

97. Graham L. ACG Releases Recommendations on the Management of Irritable Bowel Syndrome // Am. Fam. Physician. – 2009. – Vol. 15. – № 79. – P. 1108-17.

98. Greer J.B., O’Keefe S.J. Microbial induction of immunity, inflammation and cancer // Front. Physiol. – 2011. – Vol. 1. – P. 168.

99. Grisham M.B., Pavlick K.P., Laroux F.S. et al. Nitric oxide and chronic gut inflammation: controversies in inflammatorybowel disease // J. Investig. Med. – 2002. – 50. – P. 272-283.

100. Gwee K.A. Postinfectious Irritable Bowel Syndrome // Curr. Treat. Options Gastroenterol. – 2001. – Vol. 4. – P. 287-91.

101. Hamilton M. A rating scale for depression // Journal of Neurology, Neurosurgery and Psychiatry. – 1960. – Vol. 23. – P. 56-62.

102. Hamilton M. The assessment of anxiety states by rating // Br. J. Med.

Psychol. – 1959. – Vol. 32. – P. 50-55.

103. Heijtz R.D. et al. Normal gut microbiota modulates brain development and behavior // Proc. Natl. Acad. Sci. USA. – 2011. – Vol. 108. – Р. 3047-52.

104. Hosseini A., Nikfar S., Abdollahi M. Probiotics use to treat irritable bowel syndrome // Expert Opin. Biol. Ther. – 2012. – Vol. 12. – P. 1323-34.

105. Hoveyda N. et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome // BMC Gastroenterol. – 2009. – Vol. 9. – P. 15.

106. Hsu P.W., Huang H.D., Hsu S.D., Lin L.Z. et al. MiRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes // Nucleic Acids Res. – 2006. – Vol. 34 (Database issue): D135-9.

107. Huttenhower C. et al. Structure, function and diversity of the healthy human microbiome // Nature. – 2012. – Vol. 486. – P. 207-14.

108. Isolauri E., Kalliomaki M., Laitinen K., Salminen S. Modulation of the maturing gut barrier and microbiota: a novel target in allergic disease // Curr. Pharm. Des. – 2008. – Vol. 14. – P. 1368–75.

109. Jenkins D.A., Kendall C., Vuksan V. Inulin, oligofructose and intestinal function // J. Nutr. – 1999. – Vol. 129. – S1431–33.

110. Juntunen M. et al. Adherence ofprobiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection // Clin. Diagn. Lab. Immunol. – 2001. – V. 8. – S. 2. – P. 293-6.

111. Kailasapathy K. Survival and therapeutic potential ofprobiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp // J. Chin. Immunol. Cell Biol. – 2000. – V. 78. – S. 1. – P. 80-8.

112. Kassinen A., Krogius-Kurikka L., Makivuokko H. et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects // Gastroenterology. – 2007. – Vol. 133. – P. 24–33.

113. Kellow J.E., Eckersley G.M., Jones M. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome // Dig. Dis. Sci. – 1992. – Vol. 37. – P. 168-74.

114. Kerckhoffs A.P., Samsom M., Van der Rest M.E. et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients // World J. Gastroenterol. – 2009. – Vol. 15. – P. 2887–92.

115. Khachatryan Z.A., Ktsoyan Z.A., Manukyan G.P., et al. Predominant role of host genetics in controlling the composition of gut microbiota // PLoS One. – 2008. Vol. 3. – P. 3064.

116. Khan M.W., Kale A.A., Bere P., Vajjala S., Gounaris E., Pakanati K.C. Microbes, intestinal inflammation and probiotics // Expert. Rev. Gastroenterol. Hepatol. – 2012. – Vol. 6. – P. 81-94.

117. Khoshini R., Dai S.C., Lezcano S., Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth // Dig. Dis. Sci. – 2008. – Vol. 53. – N 6. – P. 1443-54.

118. Ki Cha B., Mun Jung S., Hwan Choi C., et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea- dominant irritable bowel syndrome: a randomized, double-blind, placebo- controlled trial // J. Clin. Gastroenterol. – 2012. – Vol. 46. – P. 220-7.

119. King C.E., Toskes P.P. Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth // Gastroenterology. – 1986. – Vol. 91. – P.1447-51.

120. Kong W.M., Gong J., Dong L., Xu J.R. Changes of tight junction claudin-1,- 3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome // Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao. – 2007. – Vol. 27(9). – P. 1345-7.

121. Krogius-Kurikka L., Lyra A., Malinen E. et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers // BMC Gastroenterol. – 2009. – Vol. 9. – P. 95.

122. Labow B.I., Souba W.W. Glutamine // World J. Surg. – 2000. – Vol. 24(12).

– P. 1503–13.

123. Law D., Pimentel M. Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS // Dig. Dis. Sci. – 2010. – Vol. 55. – Issue. 8. – P. 2302-8.

124. Lederberg J., McCray A.T. “Ome sweet” omics – a genealogical treasury of words // Scientist. – 2001. – Vol. 15. – P. 8.

125. Lee B.J., Bak Y.T. Irritable bowel syndrome, gut microbiota and probiotics //

J. Neurogastroenterol. Motil. – 2011. – Vol. 17. – P. 252-66.

126. Levitt MD. Production and excretion of hydrogen gas in man // N. Engl. J. Med. –1969. – Vol. 281. – P.122-7.

127. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets // Cell. – 2005. – Vol. 120. – N. 1. – P. 15-20.

128. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time // Scand. J. Gastroenterol. – 1997. – Vol. 32. – N. 9 – Р. 920–24.

129. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon

J.I. Obesity alters gut microbial ecology // Proc. Natl. Acad. Sci. USA. – 2005. – Vol. 102. – P. 11070–5.

130. Liebregts T., Adam B. et al. Immune activation in patients with irritable bowel syndrome // Gastroenterology. – 2007. – Vol. 132. – № 3. – P. 913-20.

131. Liu Y., Fatheree N.Y., Mangalat N., Rhoads J.M. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation // Am. J. Physiol. Gastrointest. Liver Physiol. – 2010. – Vol. 299. – P. 1087- 96.

132. Lobo B., Vicario M., Martinez C. et al. Clinical improvement in IBS after disodium cromoglycate involves mast cell-mediated toll-like receptor signaling downregulation // Gut. – 2010. – Vol. 59. – A52.

133. Longstreth G.F., Thompson W.G. et al. Funcional Bowel disorders // Gastroenterology. – 2006. – N 130. – P. 1490-1.

134. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis // Clin. Gastroenterol. Hepatol. – 2012. – Vol. 10(7). – P. 712-21.

135. Macsharry J., O'Mahony L., Fanning A. et al. Mucosal cytokine imbalance in irritable bowel syndrome // Scand J Gastroenterol. – 2008. – Vol. 43. – № 12. – P. 1467-76.

136. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial // Adv. Med. Sci. – 2007. – Vol. 52. – P. 139–42.

137. Malinen E., Rinttilä T., Kajander K. et al. Analysis of the microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR // Am. J. Gastroenterol. – 2005. – Vol. 100. – P. 373–82.

138. Mätto J. et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects // FEMS Immunol. Med. Microbiol. – 2005. – Vol. 1. –f № 43. – P. 213-22.

139. McCartney A.L. Application of molecular biological methods for studying probiotics and the gut flora // Br. J. Nutr. – 2002. – Vol.88 (Suppl 1). – P.29– 37.

140. Mete R., Tulubas F., Oran M. et al. The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation // Med. Sci. Monit. – 2013. – Vol. 13. – P. 762-6

141. Michelsen K.S., Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology // Curr. Opin. Hematol. – 2007. – Vol. 14 (1). – P. 48-54.

142. Moayyedi P., Ford A. et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review // Gut. – 2010. – Vol. 59. – Р. 325-32.

143. Morgan X.C., Huttenhower C. Chapter 12: Human Microbiome Analysis // PLoS Comput. Biol. – 2012. – Vol.8 (Suppl.12).

144. Motzer S.A., Jarrett M., Heitkemper M.M. et al. Natural killer cell function and psychological distress in women with and without irritable bowel syndrome // Biol Res Nurs. – 2002. –Vol. 4. – №1. – P. 31-42.

145. Mulak A, Paradowski L. Anorectal function and dyssynergic defecation in different subgroups of patients with irritable bowel syndrome // Int. J

.Colorectal. Dis. – 2010. – Vol. 25. – P. 1011-6.

146. Musso G., Gambino R., Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? // Diabetes Care. – 2010. – Vol. 33. –P. 2277-84.

147. Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: recent advances // Inflamm. Bowel Dis. – 2009. – Vol. 15. – P. 300–10.

148. Nobaek S., Johansson M.L., Molin G., Ahrne S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome // Am. J. Gastroenterol. – 2000. – Vol. 95. – P. 1231–8.

149. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth // Aliment. Pharmacol. Ther. – 2005. – Vol. 21. – P. 1391–5.

150. O’Connell R.M., Rao D.S., Chaudhuri A.A. et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder // J. Exp. Med. – 2008. – Vol. 205. – P. 585–94.

151. O'Brien SM1, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment // Hum. Psychopharmacol. – 2004. – Vol. 19. – № 6. – P. 397-403.

152. Ohland С., MacNaughton К. Probiotic bacteria and intestinal epithelial barrier function // American Journal of Physiology, Gastrointestinal and Liver Physiology. – 2010. – Vol. 298. – Р. 807–19.

153. Ohman L., Lindmark A.C., Isaksson S. et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients // Eur. J. Gastroenterol. Hepatol. – 2012. – Vol. 24. – №4. – P. 398-405.

154. O'Mahony L., Mccarthy J. et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles // Gastroenterology. – 2005. – Vol. 128. – №3. – Р. 541–51.

155. Ott S.J., Musfeldt M. et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease // Gut. – 2004. – Vol. 53ю – №5. – P. 685-93.

156. Parkes G.C., Rayment N.B., Hudspith B.N. et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome // Neurogastroenterol. Motil. – 2012. – Vol. 24. – P. 31–9.

157. Parry S.D., Stansfield R. et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case- control study // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 327–31.

158. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome // Am. J. Gastroenterol. – 2000. – Vol. 95. – Р. 3503-6.

159. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study // Am. J. Gastroenterol.

– 2003. – Vol. 98. – Р. 412-9.

160. Ponnusamy K. et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces // J. Med. Microbiol. – 2011. – Vol. 60. – Р. 817-27.

161. Prakash S., Rodes L., Coussa-Charley M. et al. Gut microbiota: next frontier in understanding human health and development of biotherapeutics // Biologics. – 2011. – Vol. 5. – Р. 71-86.

162. Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects // Gut. – 1990. – Vol. 31. – P. 458-62.

163. Proal A.D., Albert P.J., Marshall T. Autoimmune disease in the era of the metagenome // Autoimmun. Rev. – 2009. – Vol. 8. – P. 677-81.

164. Qin J., Li R., Raes J., Arumugam M. et al. A human gut microbial gene catalogue established by metagenomic sequencing. MetaHIT Consortium // Nature. – 2010. – Vol. 464. – Р. 59-65.

165. Quigley E., Thompson J. The motor response to intestinal resection: motor activity in the canine small intestine following distal resection // Gastroenterology. – 1993. – Vol. 105. – P. 791-8.

166. Quigley E.M. Intestinal dysmotility and the irritable bowel syndrome // Ir. J. Med. Sci. – 1994. – Vol. 163. – P. 560-1.

167. Quigley EM. Microflora modulation of motility // J. Neurogastroenterol.

Motil. – 2011. – Vol. 17. – P. 140-7.

168. Rajilić-Stojanović М et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome // Gastroenterology. – 2011. – Vol. 141. – Р. 1792–1801.

169. Rambaud J-C et al. Gut Microflora. Digestive physiology and pathology.

John Libbey Eurotext. Paris. 2006.

170. Rinttila T., Lyra A., Krogius-Kurikka L. et al. Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects // Gut Pathog. – 2011. – Vol. 3. – P. 6.

171. Riordan S.M., McIver C.J., Walker B.M. et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth // Am. J. Gastroenterol. – 1996. – Vol. 91. – P. 1795-803.

172. Romero-Valdovinos M., Gudiño-Ramirez A., Reyes-Gordillo J. Interleukin- 8 and -10 gene polymorphisms in irritable bowel syndrome // Mol. Biol. Rep. – 2012. – Vol. 39. – P. 8837-43.

173. Rumessen JJ, Gudmand-Hoyer E, Bachmann E, et al. Diagnosis of bacterial overgrowth of the small intestine. Comparison of the 14CD-xylose breath test and jejunal cultures in 60 patient // Scand. J. Gastroenterol. – 1985. – Vol. 20. – P. 1267-75.

174. Saleh M., Elson C. Experimental inflammatory bowel disease: insights into the host-microbiota dialogue // Immunity. – 2011. – Vol. 34. – P. 293–302.

175. Scheppach W. Effects of short chain fatty acids on gut morphology and function // Gut. – 1994. – Vol. 35 (suppl. 1). – P. 35–38

176. Sears С.L. Enterotoxigenic Bacteroides fragilis: a Rogue among Symbiotes // Clin. Microbiol. Rev. – 2009. – Vol. 22. – P. 349–69.

177. Sekirov I., Russell S.L., Antunes L.C., Finlay B.B. Gut microbiota in health and disease // Physiol. Rev. – 2010. – Vol. 90. – Р. 859–904.

178. Shah E.D., Basseri R.J., Chong K., Pimentel M. Abnormal breath testing in IBS: a meta-analysis // Dig. Dis. Sci. – 2010. – Vol. 55. – P. 2441-9.

179. Shah V., Lyford G., Gores G. et al. Nitric oxide in gastrointestinal health and disease // Gastroenterology. – 2004. – 126. – P. 903-913.

180. Sharp P.A. RNA interference-2001 // Genes. Dev. – 2001. – Vol. 1. – № 15.

– P. 485-90.

181. Shivdasani R.A. MicroRNAs: regulators of gene expression and cell differentiation // Blood. – 2006. – Vol. 108. – P. 3646-53.

182. Si J.M., Yu Y.C., Fan Y.J., Chen S.J. Intestinal microecology and quality of life in irritable bowel syndrome patients // World J. Gastroenterol. – 2004. – Vol. 10. – P. 1802-5.

183. Silk D.B., Davis A., Vulevic J., et al. Clinical trial: the effects of a trans- galactooligosaccharide prebiotic on faecal microbiota and symptoms in

irritable bowel syndrome // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 508–18.

184. Simren M. and P‐O Stotzer. Use and abuse of hydrogen breath tests // Gut. –

2006. – Vol.55 (Suppl.3). – P. 297-303.

185. Singh N. et al. The murine caecal microRNA signature depends on the presence of the endogenous microbiota // Int. J. Biol. Sci. – 2012. – Vol. 8. – P. 171-86.

186. Spiller R.S. Post-infectious IBS // Camilleri M., Spiller R.C. Irritable bowel syndrome. Diagnostic and treatment. – W.B. Saunders, 2002.

187. Spinucci G., Guidetti M., Lanzoni E., Pironi L. Endogenousethanol production in a patient with chronic intestinal pseudoobstruction and small intestinal bacterial overgrowth // Eur. J. Gastroenterol. Hepatol. – 2006. – Vol. 18. – N 7. – Р. 799-802.

188. Srikanth C.V., McCormick B.A. Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk // Interdiscip. Perspect. Infect. Dis. – 2008. – Vol. 27. – P.62-8.

189. Steer T., Carpenter H., Tuohy K., Gibson G.R. Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics // Nutrition Research Reviews. – 2000. – Vol. 13. – P. 229–54.

190. Suzuki T., Seth A., Rao R. Role of phospholipase Cgamma-induced activation of protein kinase Cepsilon (PKCepsilon) and PKCbetaI in epidermal growth factor-mediated protection of tight junctions from acetaldehyde in Caco-2 cell monolayers // J. Biol. Chem. – 2008. – Vol. 283.

– Р. 574-83.

191. Taganov K.D., Boldin M.P., Baltimore D. MicroRNAs and immunity: tiny players in a big field // Immunity. – 2007. – Vol. 26. – P. 133-7.

192. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin

of symptoms in irritable bowel syndrome // Neurogastroenterol. Motil. – 2010. – Vol. 22. – P. 512-9.

193. Tap J., Mondot S. et al. Towards the human intestinal microbiota phylogenetic core // Environ Microbiol. – 2009. – Vol. 11. – P. 2574-84.

194. Thim L., Madsen F., Poulsen S.S. Effect of trefoil factors on the viscoelastic properties of mucus gels // Eur. J. Clin. Investig. – 2002. – Vol. 32. – P. 519– 27.

195. Thompson J., Quigley E., Adrian T. Qualitative changes in enteric flora and short-chain fatty acids after intestinal resection // Dig. Dis. Sci. – 1998. – Vol. 43. – P. 624-31.

196. Tsukita S., Furuse M., Itoh M. Multifunctional strands in tight junctions // Nature Rev. Mol. Cell Biol. – 2001. – Vol. 2. – P. 285–93.

197. Turksen K., Troy T.C. Barriers built on claudins // J. Cell Sci. – 2004. – Vol.

117. – P. 2435–47.

198. Turnbaugh P.J., Ley R.E., Hamady M. et al. The human microbiome project

// Nature. – 2007. – Vol. 449. – Р. 804–10.

199. Turnbull A.V., Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action // Physiol. Rev. – 1999.

– V. 79. – P. 1-71.

200. Urbanska A.M., Bhathena J., Martoni C., Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc (Min/+) mice

// Dig. Dis. Sci. – 2009. – Vol. 54. – P. 264–73.

201. Vaishnava S., Yamamoto M., Severson K.M. et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine // Science. – 2011. – Vol. 334. – P. 255-8.

202. Veiga P. et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes // Proc. Natl. Acad. Sci. USA. – 2010. – Vol. 107. – Р. 18132-7.

203. Voorhoeve P.M., Agami R. Knockdown stands up // Trends Biotechnol. – 2003. – Vol. 21(1). – P. 2-4.

204. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey.

Manual and interpretation guide //The Health Institute, New England Medical Center. Boston, Mass. – 1993.

205. Weaver M.E., Lowe N.K. A critical review of visual analogue scales in the measurement of clinical phenomena // Res. Nurs. Health. – 1990. – Vol. 13.

– N. 4. – P. 227-36.

206. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1581–90.

207. Xu J., Gordon J.I. Honor thy symbionts // Proc. Natl. Acad. Sci. USA. – 2003. – Vol. 100. – P. 10452–9.

208. Yan F et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism // J. Clin. Invest. – 2011. – Vol. 121. – Р. 2242-53.

209. Yu D., Cheeseman F., Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro- caecal transit, not small intestinal bacterial overgrowth in patients with IBS // Gut. – 2011. – Vol. 60. – Р. 334–40.

210. Yun C.H. et al. Mammalian Na+/H+ exchanger gene family: structure and function studies // Am. J. Physiol. – 1995. – Vol. 269. – P. 1-11.

211. Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients

with diarrhoea-predominant irritable bowel syndrome // Aliment. Pharmacol. Ther. – 2008. – Vol. 28. – P. 994–1002.

212. Zhou Q., Souba W.W., Croce C.M., Verne G.N. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome // Gut. – 2010. – Vol. 59. – P. 775-84.

213. Zoetendal E.G., Vaughan E.E., de Vos W.M. A microbial world within us // Mol. Microbiol. – 2006. – Vol. 59. – Р. 1639-50.

<< | >>
Источник: КУЧУМОВА Светлана Юрьевна. Патогенетическое и клиническое значение кишечной микрофлоры у больных с синдромом раздраженного кишечника». Диссертация на соискание ученой степени кандидата медицинских наук. Москва –2014. 2014

Еще по теме Список литературы:

  1. СПИСОК ЛИТЕРАТУРЫ
  2. СПИСОК ЛИТЕРАТУРЫ
  3. Список литературы:
  4. Список литературы
  5. СПИСОК ЛИТЕРАТУРЫ
  6. СПИСОК ЛИТЕРАТУРЫ
  7. СПИСОК ЛИТЕРАТУРЫ
  8. Список литературы
  9. СПИСОК ЛИТЕРАТУРЫ:
  10. Список литературы
  11. Список литературы
  12. СПИСОК ЛИТЕРАТУРЫ
  13. СПИСОК ЛИТЕРАТУРЫ
  14. СПИСОК ЛИТЕРАТУРЫ
  15. Список литературы
  16. СПИСОК ЛИТЕРАТУРЫ
  17. Список литературы
  18. Список литературы
  19. Список литературы